A Comparison of Dorzolamide and Timolol in Patients with Pseudoexfoliation and Glaucoma or Ocular Hypertension
References (34)
- et al.
MK-507 versus sezolamide
Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology
(1991) - et al.
Exfoliation syndrome
Am J Ophthalmol
(1974) - et al.
The presentation and prognosis of glaucoma in pseudoexfoliation of the lens capsule
Ophthalmology
(1988) Prevalence of pseudo-exfoliation syndrome in an urban South African clinic population
Am J Ophthalmol
(1972)- et al.
Long-term followup of pseudoexfoliation and the development of elevated intraocular pressure
Ophthalmology
(1987) Carbonic anhydrase: chemistry, physiology and inhibition
Physiol Rev
(1967)Diuretics and other agents employed in the mobilization of edema fluid
Carbonic anhydrase: general perspectives and advances in glaucoma research
Drug Dev Res
(1987)Topical carbonic anhydrase inhibitors
Ophthalmol Clin North Am
(1989)- et al.
The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys
Arch Ophthalmol
(1990)
A comparison of L-671,152 and MK-927, two topically effective ocular hypotensive carbonic anhydrase inhibitors, in experimental animals
Curr Eye Res
(1990)
MK-927: a topically effective carbonic anhydrase inhibitor in patients
Arch Ophthalmol
(1989)
MK-927: a topical carbonic anhydrase inhibitor
Dose response and duration of action. Arch Ophthalmol
(1990)
Multiple-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927
Arch Ophthalmol
(1991)
Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927
Arch Ophthalmol
(1991)
Treatment of chronic open-angle glaucoma associated with pseudoexfoliation
Acta Ophthalmol Scand
(1965)
Exfoliation syndrome: incidence and prognosis of glaucoma capsulare in Massachusetts
Arch Ophthalmol
(1966)
Cited by (0)
- **
Dr. Strahlman and Mr. Tipping were employees of Merck & Co, Inc, the manufacturer of dorzolamide, at the time this study was conducted.
- ***
Dr. Strahlman currently is the Vice President of Corporate Medical Affairs for Bausch & Lomb.
Copyright © 1997 American Academy of Ophthalmology, Inc. Published by Elsevier Inc. All rights reserved.